Evidence map›Paper›PMID 33119168›Full record

ArticleAlimentary pharmacology & therapeutics2020

Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.

Sushrut Jangi, Hyuk Yoon, Parambir S Dulai, Mark Valasek, Brigid S Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Disease Clearance in Ulcerative Colitis: A Narrative Review.United European gastroenterology journal · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sushrut JangiDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0001-5488-5770
Hyuk YoonDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Parambir S DulaiDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-9514-2321
Mark ValasekDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Brigid S BolandDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Vipul JairathWestern University, London, ON, Canada.ORCID https://orcid.org/0000-0002-1092-0033
Brian G FeaganWestern University, London, ON, Canada.ORCID https://orcid.org/0000-0002-6914-3822
William J SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-3314-7960
Siddharth SinghDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-2640-7269

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NCATS NIH HHS KL2 TR001444NIDDK NIH HHS K23 DK117058NIDDK NIH HHS P30 DK120515NIH HHS KL2TR001444
6 · The paper itself

Abstract

backgroundClinical remission is the recommended treatment target in ulcerative colitis. The predictors and outcomes of achieving histologic remission within a treat-to-target paradigm are not well established.

aimTo evaluate the predictors and outcomes of achieving histologic remission in patients with ulcerative colitis treated-to-target of endoscopic healing (modified Mayo endoscopy score 0 or 1).

methodsWe conducted a retrospective cohort study in adults with active ulcerative colitis (modified Mayo endoscopy score 2 or 3), whose treatment was iteratively optimised to achieve endoscopic healing. We identified predictors of achieving histologic remission, and outcomes (risk of symptomatic relapse, and ulcerative colitis-related hospitalisation and/or surgery) of achieving histologic remission vs persistent histologic activity, using Cox proportional hazard analysis.

resultsOf the 411 patients with clinically active ulcerative colitis, 270 achieved endoscopic healing. Of the 270 patients, 55% simultaneously achieved histologic remission. Depth of endoscopic healing at final endoscopic assessment was the only independent determinant of histologic remission (modified Mayo endoscopy score 0 vs 1: odds ratio, 0.31 [95% confidence intervals, 0.18-0.52]). Over 28 months, achieving histologic remission was associated with a lower risk of clinical relapse (1-year cumulative risk: 18.7% vs 29.5%; adjusted hazard ratio, 0.56 [0.37-0.85]), and lower risk of hospitalisation (hazard ratio, 0.44 [0.20-0.94]). The incremental benefit of achieving histologic remission was observed only in patients achieving Mayo endoscopy score 1, but not Mayo endoscopy score 0.

conclusionsIn patients with active ulcerative colitis treated-to-target of endoscopic healing, 55% simultaneously achieved histologic remission. Histologic remission, particularly in patients achieving modified Mayo endoscopy score 1, was associated with favourable outcomes. Treating to a target of histologic remission over endoscopic healing requires prospective evaluation.

Indexed as

ColonoscopyAdultColitis, UlcerativeFemaleHumansMaleMiddle AgedRecurrenceRemission InductionRetrospective StudiesSeverity of Illness Index

Identifiers

PMID33119168
PMCPMC8965793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.